⌘K

08:49:15·72d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.

ByQuantisnow·Wall Street's wire, on your screen.

TSHA· Taysha Gene Therapies Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

TSHA
Taysha Gene Therapies Inc.
Health Care

Recent analyst ratings

Oct 21UpdateRaymond James$13.00
Jul 11UpdateBofA Securities$8.00
Jun 27UpdateBMO Capital Markets$5.00
Apr 9UpdatePiper Sandler$9.00
Feb 1UpdateJefferies$1.50
Jan 27UpdateMorgan Stanley$3.00

Related

PR1d
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
PR3d
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
SEC8d
SEC Form DEFA14A filed by Taysha Gene Therapies Inc.
SEC8d
SEC Form DEF 14A filed by Taysha Gene Therapies Inc.
INSIDER17d
SEC Form 4 filed by Nagendran Sukumar
SEC20d
SEC Form 144 filed by Taysha Gene Therapies Inc.
PR27d
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SEC42d
SEC Form 10-K filed by Taysha Gene Therapies Inc.